Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Lowered to Hold at Wall Street Zen

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently commented on the stock. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price for the company. Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. Piper Sandler raised their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $293.45.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $234.76 on Friday. The company has a 50 day moving average price of $229.39 and a 200-day moving average price of $217.74. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The firm has a market capitalization of $15.07 billion, a PE ratio of 79.85, a P/E/G ratio of 0.43 and a beta of 0.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company earned $8.13 earnings per share. As a group, equities research analysts expect that Jazz Pharmaceuticals will post 11.08 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the transaction, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the transaction, the director owned 339,875 shares in the company, valued at $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,534 shares of company stock valued at $25,185,243 in the last three months. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of JAZZ. Aberdeen Group plc increased its stake in Jazz Pharmaceuticals by 16.5% in the 3rd quarter. Aberdeen Group plc now owns 97,422 shares of the specialty pharmaceutical company’s stock worth $22,555,000 after buying an additional 13,816 shares in the last quarter. JW Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the third quarter valued at about $2,547,000. Russell Investments Group Ltd. lifted its position in shares of Jazz Pharmaceuticals by 50.6% in the third quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock valued at $17,696,000 after acquiring an additional 25,671 shares in the last quarter. Eurizon Capital SGR S.p.A. lifted its position in shares of Jazz Pharmaceuticals by 46.1% in the third quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $757,000 after acquiring an additional 1,029 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in shares of Jazz Pharmaceuticals by 19.0% in the third quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock worth $841,000 after acquiring an additional 580 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.